SCHEMBL8819342

SCHEMBL8819342

CC(=O)OC1C(OC(C)=O)[C@@H](CF)O[C@H]1n1cnc2c(NOCc3ccccc3)nc(Cl)nc21

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
MAPT P10636 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
ACHE P22303 4/20 0.54
ADORA3 P0DMS8 3/20 0.53
NT5E P21589 5/20 0.48
PRKAB2 O43741 1/20 0.45
PRKAG1 P54619 1/20 0.45
PRKAA2 P54646 1/20 0.45
PRKAA1 Q13131 1/20 0.45
PRKAG3 Q9UGI9 1/20 0.45
PRKAG2 Q9UGJ0 1/20 0.45
PRKAB1 Q9Y478 1/20 0.45
PDE2A O00408 2/20 0.45
ADORA1 P30542 2/20 0.45
ADORA2A P29274 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8820284 1.00 ALDH1A1 (0.55) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL7627010 0.84 ADORA3 (0.60) ADORA3NT5EADORA1ADORA2A
SCHEMBL7627041 0.84 ADORA3 (0.60) ADORA3NT5EADORA1ADORA2A
SCHEMBL8819182 0.83 ALDH1A1 (0.51) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL9404051 0.83 ALDH1A1 (0.51) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL24601162 0.80 ALDH1A1 (0.70) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL8819416 0.80 ALDH1A1 (0.57) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL8820548 0.78 ADORA1 (0.70) ADORA3ADORA1ADORA2A
SCHEMBL8820317 0.78 ALDH1A1 (0.67) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL8820534 0.78 ADORA1 (0.70) ADORA3ADORA1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1997033590-A1 A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS NOVO NORDISK A/S (DK) 1997-09-18 WO disclosed